Phex is an endopetidase that regulates systemic phosphate homeostasis. We 
P
HEX IS A zinc metalloproteinase whose physiologic function is to regulate unidentified substrates controlling circulating phosphate concentrations and skeletal mineralization (1, 2) . Phex is expressed in the skeleton, as well as in a limited number of other tissues including lung, ovary, testis, parathyroid gland, and brain (3) (4) (5) (6) . Investigations of the hereditary diseases X-linked hypophosphatemia and the Hyp mouse animal homologue, which have inactivating Phex mutations, have provided insights into the complex pathogenesis of phosphaturia and impaired skeletal mineralization (1, 2, 7) . It is likely that inactivating mutations of Phex indirectly causes renal phosphate wasting and hypophosphatemia by its failure to metabolize a putative phosphateregulating hormone, phosphatonin, that has not yet been identified (2, 8, 9) . In addition, Phex seems to play a role in regulating skeletal mineralization independent of hypophosphatemia, as evidenced by Phex expression in mature osteoblasts (3, 5) , the finding that the loss of Phex function in osteoblasts derived from Hyp mice causes an intrinsic defect in mineralization of extracellular matrix in vitro (10, 11) and the partial rescue of the phenotype by bone marrow transplantation (12) .
Limited information is available regarding the regulation of Phex. Given its role in systemic phosphate homeostasis and skeletal mineralization, and the multitude of factors regulating mineral ion homeostasis, such as age, sex, diet, PTH, and vitamin D, it is likely that Phex expression is regulated (2) . Recent studies demonstrate that Phex expression in bone is increased by IGF-I and down-regulated by PTH administration and aging (13) . Other studies indicate that a low phosphorus diet increases Phex transcripts in the pituitary gland but not in bone as assessed by semiquantitative RT-PCR analysis (14) . In the skeleton, Phex is one of a group of cell-restricted genes that displays a late developmental expression pattern in mineralizing bone and cartilage, where this endopeptidase is predominantly expressed in mature osteoblasts and hypertrophic chondrocytes that are involved in regulation mineralization of extracellular matrix (3, 10, 15) . Thus, cell-type and/or tissue-specific factors are likely responsible for the restricted pattern of Phex expression. Additional studies are needed to characterize molecular mechanisms of cell-type and tissue-specific expression of Phex and its regulation by factors controlling mineral homeostasis. Identification and characterization of the Phex gene promoter are important steps in defining the role of transcriptional regulation of the Phex gene.
In the current studies, we describe the cloning, sequencing, and functional analysis of the murine Phex promoter. We found that osteoblasts and chondrocytes express Phex endogenously and have the trans-acting factors necessary to direct transcription of the transfected Phex promoter. In contrast, COS-7 cells lack the necessary transcriptional machinery needed for Phex expression, suggesting that regulatory regions of the murine Phex promoter may function in a cellspecific manner. SOX9, a master regulatory factor for chondrocyte differentiation, stimulated the promoter activity, whereas the osteoblastic differentiation factor Cbfa1 had no effect on Phex promoter activity. We failed to identify either 1,25(OH) 2 D 3 or PTH regulation of the transfected Phex promoter, suggesting any effects of these agents on Phex may not be mediated by transcriptional mechanisms or that the Phex promoter region lacks the necessary regulatory elements.
Materials and Methods

Isolation of the murine Phex 5Ј-flanking region
A mouse 129 SVJ genomic library (Stratagene, La Jolla, CA) was screened with a cDNA probe derived from mouse Phex exon 1 (oligoAbbreviations: G3PDH, Glyceraldehyde-3-phosphate dehydrogenase; RT, reverse transcriptase; TPA, 12-O-tetradecanoylphorbol-13-acetate; UTR, untranslated region. nucloeotides ϩ432 to ϩ547). The probe was labeled with ␣-32 P dCTP (800Ci/mmol) using a random primer DNA labeling kit (Life Technologies, Inc., Grand Island, NY). Plaque lifting, prehybridization, hybridization, washing of the filters, and autoradiography were performed by standard methods. Nine positive clones were identified after screening 1 ϫ 10 6 pfu at a density of 5 ϫ 10 4 pfu/plate. Putative positive clones were purified by secondary and tertiary rounds of screening. Restriction digests with Nsi I and Southern blot analysis with the exon 1 cDNA probe identified two clones containing identical 5Ј-flanking regions. A 12-kb fragment was released from this phage clone and partially sequenced, revealing 1104 bp of intron 1, 674 bp exon 1, and approximately 10.2 kb of the 5Ј-flanking sequence. This promoter sequence has been entered in GenBank, accession number AF299334.
The promoter analysis program Neural Network Promoter Prediction (http://www.fruitfly.org/seq_tools/promoter.html) was used to predict the transcription start site. The promoter sequence was analyzed by the Transcription Element Search System (TESS of the Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania, http://agave.humgen.upenn.edu/tess/index.html) by using a 6-bp minimum element size limit, a 5% mismatch allowance, a minimum loglikelihood of homology of 10, and a secondary log-likelihood density threshold of 1.6. Further analysis of the promoter sequence was conduced using TFSEARCH (http://pdap1.trc.rwcp.or.jp/research/db/TFSEARCH. html). In addition, we used the sequence information from the mouse Phex promoter and Blast analysis (http://www.ncbi.nlm.nih.gov/BLAST/) to identify the corresponding region of the human promoter (accession number Y10196) (16 
RT-PCR analysis
RT-PCR was performed using a two-step RNA PCR kit (Perkin-Elmer Corp., Branchburg, NJ). DNase-treated total RNA (2.5 g) was reverse transcribed into cDNA in a total volume of 50 l with random primers. The RT reaction was incubated at 42 C for 15 min. The resulting cDNA was PCR amplified using various sets of primers. Forward primers included Phex-22F (5Ј-GGGACTAACACACTGAAAGAGT-3Ј) and Phexϩ1F (5Ј-AACTTTTGACGACGACAGTTCA-3Ј). The reverse primer was Phexϩ697R (5Ј-GAAACTTAGGAGACCTTGAC-3Ј), located in exon 2. PCR was performed with thermal cycling parameters of 94 C for 30 sec, 60 C for 30 sec, and 72 C for 60 sec for 35 cycles, followed by a final extension at 72 C for 7 min. For evaluation of Phex expression in different cell lines, we used the forward primer Phexϩ1866F (5Ј-AAT-TGATTGAGGGTGTTCGC-3Ј) and the reverse primer Phexϩ2943R (5Ј-ACCCAAATAATGAAAATGCA-3). For RT-PCR analysis of 4 and 9-dold MC3T3-E1 osteoblasts, we used Phex-specific primers Phexϩ1419F (5Ј-TTGGCAAAAGTTGGCTATCCAG-3Ј) and Phexϩ965R (5Ј-TATC-CATTTCCTGTAAGCCC-3Ј) as described previously (3) . Samples without RT treatment were analyzed as controls. For evaluation of SOX9 expression, we used the forward primer 5Ј-ATCTGAAGAAGGAG-GAGCGAG-3Ј and the reverse primer 5Ј-TCAGAAGTCTCCA-GAGCTTG-3Ј, which are to regions conserved across species including mouse and primates (17) . Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) or mouse ␤-actin were amplified as controls for the amounts and integrity of RNA in the PCR reactions. RT-PCR products were identified by autoradiography using radiolabeled Phex and ␤-actin cDNA probes as described previously (3) or by ethidium bromide staining.
RNase protection analysis
RNase protection assays were used to estimate the Phex mRNA transcription start site. The riboprobe (Ϫ130, ϩ132) consisted of a 262-bp fragment of the mouse Phex subcloned into pBSK(Ϫ) (Stratagene). Single-stranded antisense radiolabeled RNA probes were transcribed from BamHI linearized Phex 262/pBSK(Ϫ) using T7 RNA polymerase and [ 32 P-]UTP (NEN Life Science Products, Boston, MA). The riboprobe was purified on a 6% polyacrylamide gel. RNase protection assays were conducted using the RPA III kit (Ambion, Inc., Austin, TX). Twenty micrograms of total RNA from each cell line and the labeled riboprobe (100,000 cpm) were precipitated, redissolved in 10 l Hybridization III Buffer and incubated overnight at 42 C. Products were digested with RNase A/RNase T1 mix (1:100 dilution) for 30 min, and the protected RNA fragments were separated on a 5% denaturing polyacrylamide gel. The resultant products were assessed by autoradiography using BioMax MS film at Ϫ70 C.
Cell culture
ROS17/2.8 osteoblasts were grown in a 1:1 mixture of DMEM and Nutrient Mixture F-12 (Life Technologies, Inc.), as described previously (18) . The MC3T3-E1 osteoblast cell line was grown in ␣-MEM (Life Technologies, Inc.) and was grown in ␣-MEM supplemented with 0.13 mm ascorbic acid and 5 mm ␤-glycerol phosphate for differentiation, as described previously (18) . COS-7 cells were maintained in DMEM (Life Technologies, Inc.) (19) . C5.18 chondrocytes (20) were provided by Dr. Jane E. Aubin (University of Toronto, Toronto, Canada) and maintained in ␣-MEM containing 15% FBS. All cell lines, except C5.18, were supplemented with 10% (vol/vol) FBS. All cultures were supplemented with 100 g/ml penicillin and streptomycin and cultured in a humidified incubator with 5% CO 2 at a temperature of 37 C.
Preparation of constructs
To generate the Phex reporter gene constructs, 2790 bp of the genomic fragment from Ϫ2736 to ϩ54 of Phex was amplified with PCR SuperMix High Fidelity (Life Technologies, Inc.) using a set of primers (Ϫ2736 F, 5Ј-GGGGTACCGCCAGTGGGGTCTTGTATGT; ϩ54 R, 5Ј-GGGGTAC-CAGATTTCTGCTATGACAGCC), and the resultant product was subcloned into KpnI site of pGL2-Basic vector named p2736Phex-luc. Sequentially, 5Ј-deletion with different primers generated constructs from Ϫ2736 to Ϫ22, including p1606Phex-luc with primer Ϫ1606 F, 5Ј-GGGG-TACCATGCATTTGCTGTCACATAT; p964Phex-luc with primer Ϫ964 F, 5Ј-GGGGTACCTGGTTAAGATATGTTAGG; p472Phex-luc with primer Ϫ472 F, 5Ј-GGGGTACCCTTAATCCTCAGGAAGCT; p178Phex-luc with primer Ϫ178 F, 5Ј-GGGGTACCAGTTCCAGTCCAAACCA-TCA; p130Phex-luc with primer Ϫ130 F, 5Ј-GGGGTACCTTGCACTGC-AATGGACTATG; and p22 F with primer Ϫ22 F, 5Ј-GGGGTACC-GGGACTAACACACTGAAAGAGT. We used the previously described SOX9 (21) and the Cbfa1 mammalian expression constructs (22) .
Transient transfection and reporter assays
Transient transfection experiments were performed using the TransFast Reagent (Promega Corp., Madison, WI) as described previously (22) . Briefly, cells were plated at a density of 1.5 ϫ 10 5 cells/well in 6-well plates 16 h before transfection. We used 1.0 g Phex promoter constructs and 0.25 g pSV ␤-galactosidase, and in cotransfection experiments we added 0.5 g SOX9 or Cbfa1 expression constructs. Luciferase activity was measured using the Luciferase Assay Kit (Promega Corp.). ␤-Galactosidase activity was measured by ␤-Galactosidase Enzyme Assay System (Promega Corp.). For the transient transfection studies, the luciferase activity was normalized by ␤-galactosidase activity by dividing luciferase activity by ␤-gal. The relative luciferase activity was then calculated by dividing the normalized luciferase activity by that obtained with the empty pGL2-Basic vector. We observed higher ␤-gal activity in Cos-7 cells, but this did not influence the relative comparisons between cell lines. For stable transfection studies in MC3T3-E1 osteoblasts, the luciferase activity was normalized for cell number by dividing luciferase activity by DNA content. The relative luciferase activity was then calculated by dividing the normalized luciferase activity by that obtained with the MC3T3-E cells stably transfected with the empty pGL2-Basic vector. For the stimulation studies, cells were incubated in serum-free medium containing 0.1%BSA for 24 h before adding different concentration of various reagents, including PTH 1-34, forskolin, 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma, St. Louis, MO), and 1,25(OH) 2 D 3 , as described previously (17) . We previously have determined the concentration of PTH and forskolin to stimulate cAMP and the concentration of TPA to stimulate PKC activity in osteoblasts (data not shown).
Stable transfection of MC3T3-E1 with Phex promoter/luciferase reporter construct
Stable transfection of MC3T3-E1 was performed by a pooled protocol as described previously (18) . MC3T3 cells were cotransfected with p2736Phex-luc and pSV2-neo in a 15:1 molecular ratio. Transfectants were selected in the presence of 700 g/ml G418 for 14 d. The cells were plated in ␣-MEM complemented with ascorbic acid and ␤-glycerol phosphate. The luciferase activities were measured on different days using the Luciferase Assay Kit (Promega Corp.). Total DNA content was determined using Picogreen dsDNA Quantitation Reagent and Kits (Molecular Probes, Inc., Eugene, OR).
Statistical analysis
We evaluated differences between groups by one-way ANOVA. All values are expressed as mean Ϯ sem. All computations were performed using the Statgraphic statistical graphics system (STSC, Inc., Rockville, MD).
Results
Isolation and cloning of the mouse Phex promoter and its 5Ј untranslated region (UTR)
At the time we initiated our studies the Phex promoter had not been isolated or cloned and the full extent of the 5Ј UTR had not been defined. To locate the Phex promoter, we isolated and cloned the region of the mouse Phex gene containing exon 1 and upstream sequences (Fig. 1) . RT-PCR and RNase protection analysis (Fig. 2 ) demonstrated that exon 1 contains 556 bp of the 5Ј UTR and evidence for TATAcontaining promoter in the 2736 bp of upstream sequence (Fig. 1) . Using computer prediction programs, we initially located the putative transcription start site 556 bp upstream of the ATG in exon 1. We performed RNase protection to confirm the location of the transcription start site ( Fig. 2A) . Using a riboprobe (Ϫ130, ϩ132), which contained 262 oligonucleotides overlapping the putative start site, we identified a single 132 bp protected fragment in both mature MC3T3-E1 and TM-Ob osteoblasts. To provide additional evidence for the location of the transcription start site, we performed RT-PCR using intron-spanning primers flanking the initiation sites and RNA derived from differentiated, Phex-expressing MC3T3-E1 osteoblasts (Fig. 2B) . Forward primer ϩ1 F in combination with the reverse primer ϩ697 R in exon 2 generated the predicted size product. In contrast, the upstream primer Ϫ22 F in combination with ϩ697 R did not amplify any product, indicating that transcription initiation begins in the segment flanked by primers Ϫ22 F and ϩ1 F (Fig. 2B) . Consistent with the designated start site, we found a consensus TATA-box at position Ϫ32 to Ϫ23 from the transcription start site (Fig. 1) .
We used the mouse Phex promoter sequence to search for homologies in the corresponding 5Ј-flanking region of the human Phex gene that has recently been sequenced (16) . The overall homology was 71% over the 2736-bp region corresponding to the mouse Phex promoter. In addition, we found five nearly identical regions between the 2736 bp of the mouse Phex promoter and the 5Ј-flanking region of the human PHEX gene. These include an identity of 96% over the first 182 bp from the transcription start site (position Ϫ182 to ϩ1) and regions exhibiting more than 82% identity at positions Ϫ2425 to Ϫ2233 (192 bp), Ϫ1959 to Ϫ1906 (53 bp), Ϫ1317 to Ϫ1267 (50 bp), and Ϫ541 to Ϫ491 (37 bp) of the mouse promoter. In addition, we observed in both human and mouse sequence many conserved consensus elements including a GRE at position Ϫ2634 (23); several SRY sites at positions Ϫ2340, Ϫ2199, Ϫ700, Ϫ468, Ϫ388, and Ϫ313 (24); GATA-1 at positions Ϫ2402, Ϫ1920, and Ϫ166 (25); AP1 at position Ϫ673 (26); MZF1 at position Ϫ1909 (27) ; HMG box at position Ϫ1900 (28); E-box at position Ϫ1934 (29); EF1 repressor at position Ϫ1643; Bcd at the position Ϫ1573 (30); AP-4 at position Ϫ1263 (31); NF-Y at position Ϫ1057 (32); C/EBP at position Ϫ928 (33); C-Rel at position Ϫ897 (34); Lmo2 complex at position Ϫ625 (35); Nkx-2.5 at position Ϫ143 (36); Skn-1 at position Ϫ94 (37); GATA-2 at position Ϫ58 (38); and a TATA box at position Ϫ32 (39). We also observed several putative cis-acting elements in the mouse sequence that were not conserved with the corresponding human 5Ј-flanking region, including a possible AML-1a binding site at position Ϫ277 (40).
Cell specificity and abundance of Phex mRNA
Before proceeding with the functional analysis of the 5Ј-flanking region of the Phex gene, we identified Phex-expressing and -nonexpressing cells. By RNase protection analysis we confirmed the osteoblast expression and differentiation stage dependency of Phex expression ( Fig. 2A and Fig. 3 ). We detected a high level of Phex expression by RNase protection assay in mature MC3T3-E1(14 d of culture) and TM-Ob (15 d of culture) osteoblasts, but failed to detect Phex transcripts in NIH3T3 fibroblasts and undifferentiated TM-Ob cells cultured for 5 d. Using RT-PCR analysis, we detected Phex transcripts in differentiated MC3T3-E1 osteoblasts, C5.18 chondrocytes and ROS17/2.8 osteosarcoma cells, but not in COS-7 cells (Fig. 3) .
Functional characterization of the Phex promoter in ROS17/2.8 osteoblasts
To begin to examine the transcription of the Phex gene, we evaluated serial deletions of Phex-luc promoter constructs in ROS17/2.8 osteosarcoma cells (Fig. 4) . Progressive 5Ј-deletion mutations of the promoter revealed a bimodal pattern of functional activity in transiently transfected ROS17/2.8 cells (Fig. 4) . The full-length promoter construct (Ϫ2736/ϩ54) was active in ROS 17/2.8 cells, and displayed a progressive reduction in promoter activity as the 5Ј-deletion mutations approached 1606 bp, relative to the transcription start site. Further deletions from 1606 to 946 bp, however, lead to an increase in promoter activity that exceed that of the fulllength promoter. Successive deletions from Ϫ946 bp lead to a progressive reduction in promoter activity in ROS17/2.8 cells, resulting in a near complete ablation with Ϫ22/ϩ54 construct.
Cell-restricted activity of the 2.7 kb and 946 bp Phex promoter constructs
Phex transgene constructs containing 946 bp and 2736 bp of upstream sequence (p946Phex-luc and p2736Phex-luc) were further tested to define the DNA regulatory regions that might direct the tissue-specific expression of Phex (Fig. 5) . Because Phex is strongly expressed in osteoblasts and chon-drocytes but is not expressed in COS-7 cells, these two Phex promoter constructs were transiently transfected into these three different cell lines. The full-length promoter construct (Ϫ2763/ϩ54) was expressed to a higher extent (approximately 3-fold) in C5.18 chondrocytes compared with COS-7 cells. The expression was also significantly greater in ROS 17/2.8 osteosarcoma cells compared with COS-7 cells, but was quantitatively less than expected from the level of Phex mRNA in osteoblasts (Fig. 3) . In all three cell lines, the overall activity of the (2736/ϩ54) construct was lower than that observed with the truncated promoter construct (Ϫ946/ϩ54). Indeed, deletion of the initial 1789 bp of the promoter resulted (Fig. 2) is shown by an arrow. Consensus cis-acting elements for known transcription factors conserved between mouse and human are underlined. The sequence is numbered relative to the transcription start site.
in nearly a 3-fold increase in promoter activity in C5.18 chondrocytes and nearly a 2-fold activity in ROS17/2.8 osteosarcoma cells and COS-7 cells. These findings suggest that the distal region of the promoter from Ϫ946 to Ϫ2736 contains inhibitory elements and the proximal 946 bp of the promoter has regulatory elements that contribute to the differential expression of Phex between osteoblasts, chondrocytes and nonosteoblastic cell lines. The results in COS-7 cells need to be interpreted with caution, because they may not simply reflect the nonosteoblastic phenotype of the cells, but the effects of their expression of SV40 T antigen.
SOX9 enhances Phex promoter activity
Because of the high levels of expression of chondrocytes, we tested the effect of transcription factors regulating chondrogenesis on Phex promoter activity. SOX9 is a transcription factor that plays a key role in chondrogenesis (21) . To examine whether SOX9 regulates the transcriptional activity of the Phex gene, the full-length Phex promoter construct (Ϫ2736/ϩ54) was cotransfected with a SOX9 expression vector into ROS17/2.8 cells (Fig. 6A) . SOX9 overexpression in C5.18 chondrocytes, ROS17/2.8 osteosarcoma cells, and COS-7 cells enhanced by approximately 6-, 4-, and 3-fold, respectively, the transcriptional activity of the full-length Phex promoter. In contrast, SOX9 failed to stimulate activity above the control plasmid using the (Ϫ946/ϩ54) construct (Fig. 6B ). These observations suggest that SOX9 may regulate Phex gene transcription through upstream SRY-like elements, possibly at positions Ϫ2340, and Ϫ2199 (23). Additional studies will be needed to confirm the importance of the putative SRY sites and identify the transcription factors that bind to them. Other factors also are likely to be involved in mediating the preferential expression of Phex in chondrocytes. Indeed, SOX9 mRNA was detected in all three cell lines (Fig. 6C ), but its ability to up-regulate promoter activity was greatest in chondrocytes. In addition, the unexpected high activity of the Phex promoter in COS-7 cells may be explained by their high level of endogenous SOX9 transcripts.
Failure of other factors to regulate the Phex promoter
We performed additional studies evaluating the effects of Cbfa1, PTH, calcium, forskolin, 1,25(OH) 2 D 3 , phosphorus, and TPA on either Phex promoter construct (Ϫ2736/ϩ54) in ROS17/2.8 cells. In contrast to the potent stimulation by SOX9 (Fig. 6) , none of these factors stimulated Phex promoter activity (data not shown). In particular, we observed no stimulation by cotransfecting the Cbfa1 expression plasmid (22) with the Phex promoter, whereas this Cbfa1 expression plasmid has been previously used by us to stimulate an osteocalcin promoter construct (22) . Similarly, 1,25(OH) 2 D 3 at concentrations that stimulated an osteocalcin promoter construct failed to stimulate the Phex promoter construct in ROS17/2.8 (Fig. 7) or MC3T3-E1 osteoblasts. PTH at concentration ranging from 5-100 nm as well as the addition of calcium to the media at concentrations ranging from 1-5 mm also failed to stimulate Phex promoter activity in ROS17/2.8 
Developmental Stage-specific Transcriptional up-regulation of the Phex promoter in MC3T3-E1 cells
Different stages of maturation were accomplished by growing MC3T3-E1 cells in media containing serum with supplemented with ascorbic acid and ␤-glycerol phosphate for various time periods (18) . To confirm the maturational up-regulation of Phex expression, we evaluated Phex promoter activity in stably transfected MC3T3-E1 osteoblasts after 4 and 9 d of culture (Fig. 8A) . We found that Phex promoter activity relative to the empty vector alone increased during this maturation period, paralleling the culture duration dependent up-regulation of endogenous Phex mRNA in these cells (Fig. 8B) .
Discussion
To initiate studies directed at identifying pathways regulating Phex expression, we have isolated, sequenced, and characterized the functional activity of the murine Phex promoter in chondrocytes, osteoblasts, and COS-7 cells. A single transcription start site was mapped, and a promoter construct containing up to 2736 bp of the 5Ј-flanking sequence was identified and shown to display functional activity in cells expressing Phex endogenously. The promoter region that we identified is the same as that independently isolated from a mouse genomic BAC clone (41) . Searching the DNA database with the mouse promoter sequence identified a corresponding highly homologous region upstream of the human PHEX coding sequence and conservation of many of the same putative regulatory cis-acting elements in the mouse and human 5Ј-flanking regions (Fig. 1) . We have begun investigations with the murine Phex promoter to de- (Fig. 3) . The promoter/reporter construct, p2736Phex-luc, consists of sequence Ϫ2736 to ϩ54 subcloned into the pGL2-Basic vector. Deletions were generated by PCR as described in Materials and Methods. In DNA transfection experiments, successive deletions of Phex-luc from Ϫ2336 to Ϫ472 decreased the level of expression 40%, whereas deletions from Ϫ130 to Ϫ22 abolished activity, indicating critical cisacting elements are present between Ϫ947 and Ϫ472, as well as between Ϫ130 and Ϫ22. Luciferase activity is relative to pGL2-Basic vector alone and expressed as a ratio to ␤-galactosidase activity to correct for transfection efficiency. Values represent the mean Ϯ SEM of a minimum of three separate transfection experiments. Values sharing the same superscript are not significantly different at P Ͻ 0.05.
FIG. 5. Function analysis of the murine
Phex promoter in different cell lines: evidence for positive and negative regulators. We compared constructs p2736Phex-luc and p946Phex-luc that, respectively, contain 2790 bp and 946 bp of the 5Ј-flanking portion of the Phex gene inserted immediately upstream from the firefly luciferase in pGL2-Basic. One microgram of pPhex-luc and 0.25 g pSV ␤-galactosidase were cotransfected into cells using TransFast reagent. The luciferase activity was normalized by ␤-galactosidase activity and expressed relative to the pGL2-basic vector. The p946Phex-luc construct demonstrated greater activity in C5.18 chondrocytes and ROS17/2.8 osteoblasts compared with non-Phex-expressing COS-7 cells. This suggests the presence of elements in the Phex promoter directing cell-restricted expression as well as nonspecific elements directing high-expression in COS-7 cells. In contrast, the p2736Phex-luc construct expressed less activity in all cell types, but maintained the relative greater activity in Phex-expressing chondrocytes compared with osteoblasts and COS-7 cells. The values represent the mean Ϯ SEM of three separate transfections. Values sharing the same superscript are not significantly different at P Ͻ 0.05.
termine the role that transcriptional regulation plays in the cell type-specific and hormonal regulation of Phex. To date, our analysis of the Phex promoter identifies three important features, namely the presence of transcriptional control of cell-restricted expression, a bimodal pattern of functional activity in 5Ј deletion mutants indicative of both positive and negative regulatory elements, and the lack of regulation by several factors involved in calcium and phosphate homeostasis.
Although the activity of this Phex promoter construct was greater in the cell lines C5.18 chondrocytes and ROS 17/2.8 osteoblasts that express Phex mRNA than nonexpressing COS-7 cells (Figs. 4 and 5) , the difference in promoter activity was not as great as expected based on the marked differences in Phex mRNA levels in C5.18 and ROS 17/2.8 compared with COS-7 cells (Fig. 3) . This is especially true for ROS17/ 2.8, which express high levels of Phex transcripts but have promoter activity only 50% greater than nonspecific activity of the promoter observed in COS-7 cells. Thus, there may be additional elements outside the existing Phex promoter construct or nontranscriptional mechanisms that may account for the apparent disparity between the level of Phex transcripts and promoter activity in ROS 17/2.8 osteoblasts. In addition, COS-7 cells, which are of the SV40 transformed monkey kidney cell line, may have high nonspecific activity of the Phex promoter construct in the absence of endogenous Phex expression, due to the transcriptional effects of the T antigen or to the expression of SOX9, which is expressed in COS-7 kidney-derived cells (Fig. 6 ) as well as in the developing collecting ducts of the metanephric kidney (42) . Nevertheless, complementary studies in MC3T3-E1 osteoblasts (Fig. 8 ) demonstrated maturational stage-dependent expression of Phex transcriptional activity (Fig. 2 ) that mirrors our previously reported increase of Phex transcripts in mature osteoblasts (3, 43) . Thus, the differential expression of the Phex promoter in chondrocytes and MC3T3-E1 osteoblasts and to a lesser extent in the ROS 17/2.8 osteoblasts, indicate that cis-acting elements are present in the Phex promoter necessary for its expression in skeletal cells. The finding of Phex in cartilage-derived cells, similar to its expression in osteoblasts, also further strengthens the association of Phex (Fig. 1) . C, RT-PCR analysis of SOX9 expression. Total RNA derived from the indicated cell lines was RT-PCR using a primer pair capable of amplifying SOX9 from both rodent and primate species. We identified the predicted size product in C5.18, ROS17/2.8 and COS-7 cells. ϩRT, with RT; ϪRT, without RT. G3PDH primers that amplify a 0.9-kb product were used as controls for RNA integrity (bottom). expression and the process of mineralization of extracellular matrix.
The high expression in skeletal cells lead us to investigate whether transcription factors that regulate chondrogenesis and osteoblastogenesis also regulate the Phex promoter. We examined the effects on Phex promoter activity of SOX9, a member of the family of SOX (SRY-type high mobility group box) genes that plays central role in chondrogenesis (41) , and Cbfa1 (core-binding factor) gene (also known as Runx2), a transcription factor that has a critical role in osteoblastic differentiation (44) . Consistent with the presence of several putative SRY sites in the Phex promoter, we found that cotransfection of SOX9 expression plasmid with the p2736 Phex-luc Phex promoter, but not the p946Phex-luc promoter, resulted in an increase in Phex promoter activity in all cells, indicating that the chondrocyte and osteoblast cells as well as the kidney-derived cell line COS-7 provide an environment to assess SOX9 effects. The response was greater in C5.18 chondroctyes (Fig. 6 ). The fact that SOX9 collaborates with other transcription factors potentially explains its greater effect in C5/18 chondrocytes (45, 46) . Additional studies will be needed to determine which of the several potential SRY sites or other sites are important in mediating SOX9 effects and the factors that cooperatively activate the Phex gene. Unexpectedly, and despite the presence of a putative AML-1-binding site at position Ϫ276 of the mouse (but not the human) promoter, cotransfection of a Cbfa1 expression plasmid with the Ϫ1606/ϩ54 Phex promoter had no effect on Phex promoter activity in ROS17/2.8. It is possible that other factors or unique combinations of known factors direct the restricted expression of Phex in osteoblasts.
Deletional analysis identified both positive and negative regulatory elements in the murine Phex promoter (Fig. 4) . Promoter activity was altered in ROS17/2.8 osteosarcoma cells by progressive 5Ј-deletion mutations and was characterized by a bimodal pattern of activity. The highest activity was observed with the Ϫ946/ϩ54 promoter construct. We found that deletions from Ϫ2736 to Ϫ1606 bp resulted in a decrease in promoter activity, but further deletion from to Ϫ946 bp restored promoter activity to their highest levels, consistent with the presence of repressor elements between Ϫ2736 and Ϫ946. In this region, we identified conserved sequences similar to the EF1 repressor TGCCACCTGAGG at position Ϫ1643/Ϫ1632 (30) and the osteocalcin gene silencer CCCCTNTCT at position Ϫ1985/Ϫ1977 (47). Further deletions from 946 to 22 bp resulted in progressive loss of promoter activity. Significant promoter activity was lost between 178 and 130 bp, suggesting that the region from 946 to 130 contains important positive cis-acting elements that regulate Phex transcription. This region contained the highest density of possible cis-acting elements conserved between the mouse and human sequences. These included two C/EBP sites, one C-Rel site, four SRY sites, two Nkx-2.5 sites, one AP-1 site, and one GATA-1 site. Whether these sites bind transcription factors and control Phex transcription will require further studies.
Finally, because of its role in the maintenance of normal serum phosphate levels and skeletal mineralization, our a priori hypothesis was that Phex gene transcription might be modulated by factors controlling calcium and phosphate homeostasis. We have been unable to demonstrate such regulation. PTH and 1,25(OH) 2 D 3 , two factors important in regulating systemic phosphate homeostasis, failed to affect the Phex promoter activity in ROS17/2.8 cells (Fig. 7) that have PTH receptors and respond to 1,25(OH) 2 D 3 at the concentrations used in this study. Despite potential AP-2 and c-REL sites, neither TPA or forskolin increased the activity of the Phex luciferase reporter gene in osteoblasts. These data suggest that any effect of PTH and/or vitamin D to modulate Phex expression may be indirect or involve elements outside the 2.7-kb region.
In conclusion, we have confirmed the presence of a functional promoter in the 5Ј-flanking region of the murine Phex gene and have identified a corresponding homologous sequence in humans. Our initial characterizations of the murine Phex promoter are consistent with cell-type and maturational stage-specific transcriptional control but not control by hormones and other factors known to control phosphate homeostasis. The induction of promoter activity by SOX9 is consistent with the expression of Phex in chondrocytes. Our cell culture data, however, may not accurately reflect the physiological and in vivo regulation of Phex, and additional studies are needed to clarify the regulation of the promoter in a more physiologically relevant setting. Indeed, understanding the transcriptional regulation of Phex in osteoblasts as well as the location of particular cis-acting elements con- trolling Phex expression await further analysis that include assessment of protein/DNA interactions and testing Phex promoter function in the context of transgenic mice.
